Clorox (CLX) Price Target Raised to $153.00 at Citigroup

Clorox (NYSE:CLX) had its price target upped by investment analysts at Citigroup from $149.00 to $153.00 in a research report issued to clients and investors on Friday. The firm presently has a “neutral” rating on the stock. Citigroup’s price objective suggests a potential downside of 0.78% from the stock’s previous close.

Other equities research analysts have also issued reports about the company. Barclays set a $138.00 price objective on Clorox and gave the stock a “hold” rating in a research report on Thursday. Deutsche Bank lifted their price objective on Clorox from $123.00 to $124.00 and gave the stock a “sell” rating in a research report on Thursday. BMO Capital Markets set a $165.00 price objective on Clorox and gave the stock a “buy” rating in a research report on Friday. UBS Group assumed coverage on Clorox in a research report on Wednesday, July 18th. They issued a “sell” rating and a $110.00 price objective on the stock. Finally, ValuEngine upgraded Clorox from a “hold” rating to a “buy” rating in a research report on Saturday, September 22nd. Four equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and four have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and an average target price of $141.64.

CLX traded up $0.47 on Friday, hitting $154.20. 1,176,690 shares of the company were exchanged, compared to its average volume of 1,205,010. The company has a debt-to-equity ratio of 3.15, a current ratio of 1.09 and a quick ratio of 0.67. Clorox has a 12 month low of $113.57 and a 12 month high of $155.23. The firm has a market cap of $19.51 billion, a price-to-earnings ratio of 24.63, a PEG ratio of 3.65 and a beta of 0.36.

Clorox (NYSE:CLX) last posted its quarterly earnings results on Wednesday, October 31st. The company reported $1.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.59 by $0.03. Clorox had a return on equity of 103.18% and a net margin of 13.44%. The business had revenue of $1.56 billion for the quarter, compared to analyst estimates of $1.53 billion. During the same period last year, the company earned $1.46 EPS. Clorox’s revenue for the quarter was up 4.2% compared to the same quarter last year. As a group, sell-side analysts anticipate that Clorox will post 6.41 EPS for the current year.

In other news, EVP Linda J. Rendle sold 382 shares of the firm’s stock in a transaction that occurred on Thursday, September 6th. The stock was sold at an average price of $148.32, for a total value of $56,658.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Laura Stein sold 12,880 shares of the firm’s stock in a transaction that occurred on Friday, August 31st. The shares were sold at an average price of $144.10, for a total value of $1,856,008.00. Following the completion of the transaction, the executive vice president now owns 74,483 shares of the company’s stock, valued at approximately $10,733,000.30. The disclosure for this sale can be found here. Over the last quarter, insiders sold 29,268 shares of company stock worth $4,196,686. Corporate insiders own 1.40% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in CLX. Cornerstone Wealth Management LLC purchased a new position in shares of Clorox in the 2nd quarter valued at approximately $105,000. Fort L.P. purchased a new position in Clorox during the second quarter valued at $129,000. Livingston Group Asset Management CO operating as Southport Capital Management purchased a new position in Clorox during the third quarter valued at $130,000. Whittier Trust Co. of Nevada Inc. raised its stake in Clorox by 1,297.4% during the second quarter. Whittier Trust Co. of Nevada Inc. now owns 1,621 shares of the company’s stock valued at $148,000 after buying an additional 1,505 shares during the last quarter. Finally, Legacy Advisors LLC purchased a new position in Clorox during the third quarter valued at $150,000. Institutional investors own 78.38% of the company’s stock.

Clorox Company Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Cleaning, Household, Lifestyle, and International. The company offers laundry additives, including bleach products under the Clorox brand, as well as Clorox 2 stain fighter and color booster; home care products primarily under the Clorox, Formula 409, Liquid-Plumr, Pine-Sol, S.O.S, and Tilex brands; naturally derived products under the Green Works brand; and professional cleaning, disinfecting, and food service products under the Clorox, Dispatch, HealthLink, Clorox Healthcare, Hidden Valley, KC Masterpiece, and Soy Vay brands.

Read More: What is a Fiduciary?

Analyst Recommendations for Clorox (NYSE:CLX)

Receive News & Ratings for Clorox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clorox and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply